Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer

Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevac...

Full description

Bibliographic Details
Main Authors: Giuliano Palumbo, Giovanna Esposito, Guido Carillio, Anna Manzo, Agnese Montanino, Vincenzo Sforza, Raffaele Costanzo, Claudia Sandomenico, Carmine La Manna, Nicola Martucci, Antonello La Rocca, Giuseppe De Luca, Maria Carmela Piccirillo, Rossella De Cecio, Francesco Perrone, Giuseppe Totaro, Paolo Muto, Carmine Picone, Nicola Normanno, Alessandro Morabito
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2020-04-01
Series:Exploration of Targeted Anti-tumor Therapy
Subjects:
lung cancer
angiogenesis
tyrosine kinase inhibitor
erlotinib
bevacizumab
Online Access:https://www.explorationpub.com/Journals/etat/Article/10028

Internet

https://www.explorationpub.com/Journals/etat/Article/10028

Similar Items